Valeant Pharmaceuticals Intl Inc (VRX) Receives Average Recommendation of “Hold” from Analysts

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) has been given a consensus rating of “Hold” by the twenty-five ratings firms that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a sell rating, nine have given a hold rating, seven have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $18.59.

VRX has been the subject of a number of research reports. Zacks Investment Research lowered Valeant Pharmaceuticals Intl from a “hold” rating to a “strong sell” rating in a research note on Saturday, January 13th. HC Wainwright increased their price target on Valeant Pharmaceuticals Intl from $17.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. Wells Fargo & Co reaffirmed a “sell” rating and set a $9.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, January 16th. TD Securities increased their price target on Valeant Pharmaceuticals Intl from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Friday, January 5th. Finally, Cantor Fitzgerald set a $25.00 price target on Valeant Pharmaceuticals Intl and gave the company a “buy” rating in a research note on Friday, January 19th.

Shares of Valeant Pharmaceuticals Intl (VRX) traded up $0.41 during midday trading on Friday, reaching $18.37. The company’s stock had a trading volume of 6,730,000 shares, compared to its average volume of 13,820,000. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 4.84. The company has a market cap of $6,410.00, a price-to-earnings ratio of 4.71, a P/E/G ratio of 0.56 and a beta of -0.42. Valeant Pharmaceuticals Intl has a 52-week low of $8.31 and a 52-week high of $24.43.

In related news, Director John Paulson acquired 344,216 shares of the business’s stock in a transaction dated Thursday, November 16th. The stock was bought at an average price of $14.40 per share, for a total transaction of $4,956,710.40. Following the transaction, the director now owns 94,559 shares of the company’s stock, valued at $1,361,649.60. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 5.87% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Paulson & CO. Inc. lifted its holdings in shares of Valeant Pharmaceuticals Intl by 12.5% in the second quarter. Paulson & CO. Inc. now owns 21,813,400 shares of the specialty pharmaceutical company’s stock valued at $377,372,000 after purchasing an additional 2,428,900 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Valeant Pharmaceuticals Intl by 122.8% in the fourth quarter. Renaissance Technologies LLC now owns 10,651,189 shares of the specialty pharmaceutical company’s stock valued at $221,332,000 after purchasing an additional 5,870,689 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Valeant Pharmaceuticals Intl by 4.2% in the second quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock valued at $125,853,000 after purchasing an additional 294,643 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Valeant Pharmaceuticals Intl by 327.6% in the third quarter. Dimensional Fund Advisors LP now owns 4,472,185 shares of the specialty pharmaceutical company’s stock valued at $64,086,000 after purchasing an additional 3,426,410 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of Valeant Pharmaceuticals Intl in the fourth quarter valued at $57,221,000. Institutional investors own 48.49% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Valeant Pharmaceuticals Intl Inc (VRX) Receives Average Recommendation of “Hold” from Analysts” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.themarketsdaily.com/2018/02/15/valeant-pharmaceuticals-intl-inc-vrx-receives-average-recommendation-of-hold-from-analysts.html.

About Valeant Pharmaceuticals Intl

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals Intl (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply